Galecto Biotech picks up Series C funding
Galecto Biotech AB, a developer of galectin modulators for the treatment of severe diseases, has raised 79 million euros in Series C financing. The investors included Novo Seeds, M Ventures, Sunstone Capital, Ysios Capital, OrbiMed, HBM Healthcare Investments, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners. As a result of the transaction, Novo Seeds is now the largest shareholder in Galecto.
26 October 2018•1 min read
